Shares of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP – Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $4.37 and traded as high as $4.39. Titan Pharmaceuticals shares last traded at $3.98, with a volume of 40,794 shares trading hands.
Analysts Set New Price Targets
Separately, StockNews.com initiated coverage on Titan Pharmaceuticals in a research note on Saturday. They issued a “sell” rating on the stock.
Get Our Latest Research Report on TTNP
Titan Pharmaceuticals Stock Up 1.5 %
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its quarterly earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) EPS for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Featured Articles
- Five stocks we like better than Titan Pharmaceuticals
- Breakout Stocks: What They Are and How to Identify Them
- Chaos and Cash: Finding Opportunity in Volatility
- What Are Dividend Champions? How to Invest in the Champions
- Realty Income: An Anchor in Volatile Markets
- What does consumer price index measure?
- Autodesk Designs Value for Investors: Uptrend Set to Continue
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
